AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22285170 — intervention group
Group type: COMPARATOR
Intervention: Total vaginal mesh (TVM)
Number of subjects: 0
Study 20808145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR)
Number of subjects: 69
Study 20808145 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 69
Study 20808145 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 69
Study 17620076 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax sublingual immunotherapy
Number of subjects: 934
Study 17620076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 934
Study 16339217 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner with special interest service
Number of subjects: 0
Study 16339217 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient care
Number of subjects: 0
Study 12148386 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 1067
Study 12148386 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 1067
Study 10417865 — intervention group
Group type: EXPERIMENTAL
Intervention: Toborinone infused at 40 micrograms/kg/min for the first 5 min and then at 10 micrograms/kg/min for 85 min (Group A)
Number of subjects: 12
Study 10417865 — intervention group
Group type: EXPERIMENTAL
Intervention: Toborinone infused at 10 micrograms/kg/min for the entire 90 min (Group B)
Number of subjects: 12
Study 10417865 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 12
Study 8644363 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Contrast Barium Enema (DCBE)
Number of subjects: 44
Study 8644363 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 44
Study 1710098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (4 x 10(6) KIU) as a continuous infusion and 2 x 10(6) KIU added to pump prime
Number of subjects: 80
Study 1710098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1710098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 80
Study 6797734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study 6797734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 0
Study 6797734 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrityl trinitrate
Number of subjects: 0
Study 6797734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31762390 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Deficits
Number of subjects: 147
Study 31762390 — intervention group
Group type: EXPERIMENTAL
Intervention: Asociality
Number of subjects: 147
Study 30237010 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (10 sessions, 10 Hz applied over the left dorsolateral prefrontal cortex)
Number of subjects: 117
Study 28716146 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly mobile phone text messaging plus motivational interviewing and usual standard of care
Number of subjects: 60
Study 28716146 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care
Number of subjects: 60
Study 25581826 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine alone
Number of subjects: 508
Study 25581826 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus Azathioprine
Number of subjects: 508
Study 24189760 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-1227
Number of subjects: 60
Study 24189760 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine/Chondroitin sulfate
Number of subjects: 60
Study 21289601 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 35
Study 21289601 — intervention group
Group type: EXPERIMENTAL
Intervention: mCPP
Number of subjects: 35
Study 21289601 — intervention group
Group type: COMPARATOR
Intervention: saline infusion
Number of subjects: 35
Study 21289601 — intervention group
Group type: COMPARATOR
Intervention: acamprosate (2997 mg daily)
Number of subjects: 35
Study 19712767 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG-containing malaria vaccine
Number of subjects: 0
Study 19712767 — intervention group
Group type: COMPARATOR
Intervention: Control (no CpG)
Number of subjects: 0
Study 17200316 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg orally per week for three months)
Number of subjects: 16
Study 17200316 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control Group B)
Number of subjects: 16
Study 12947133 — intervention group
Group type: EXPERIMENTAL
Intervention: Field conditions
Number of subjects: 32
Study 12947133 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised conditions
Number of subjects: 32
Study 11186684 — intervention group
Group type: EXPERIMENTAL
Intervention: Marberger resectoscope
Number of subjects: 203
Study 11186684 — intervention group
Group type: COMPARATOR
Intervention: Standard resectoscope
Number of subjects: 203
Study 8610656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (200,000 IU oil-soluble)
Number of subjects: 200
Study 8610656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1426388 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin acetate plus gonadotropins (group B)
Number of subjects: 35
Study 1426388 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate plus gonadotropins (group L)
Number of subjects: 35
Study 3860035 — intervention group
Group type: EXPERIMENTAL
Intervention: HTF medium under oil for fertilization and culture
Number of subjects: 0
Study 3860035 — intervention group
Group type: COMPARATOR
Intervention: Modified Tyrode's medium
Number of subjects: 0
Study 3860035 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture in medium under oil
Number of subjects: 0
Study 3860035 — intervention group
Group type: COMPARATOR
Intervention: Culture in loosely capped tubes
Number of subjects: 0
Study 3549706 — intervention group
Group type: EXPERIMENTAL
Intervention: External arteriovenous shunts
Number of subjects: 67
Study 3549706 — intervention group
Group type: COMPARATOR
Intervention: Modified right atrial catheters
Number of subjects: 67
Study 30545350 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (long-acting muscarinic antagonist and long-acting β2-agonist/inhaled corticosteroid)
Number of subjects: 360
Study 30545350 — intervention group
Group type: COMPARATOR
Intervention: Dual bronchodilator (ICS withdrawal)
Number of subjects: 360
Study 30545350 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exacerbation (both groups)
Number of subjects: 360
Study 25795414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity unsupervised walking exercise intervention for 4 months
Number of subjects: 14
Study 23818351 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX chemotherapy (3 cycles)
Number of subjects: 38
Study 20533638 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum oxide‐impregnated polymer points (Enhance Finishing System, Dentsply) followed by diamond‐impregnated micropolishing points (PoGo, Dentsply)
Number of subjects: 40
Study 20533638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanotechnology liquid polish system (Lasting Touch, Dentsply)
Number of subjects: 40
Study 20533638 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum oxide‐impregnated polymer points and diamond‐impregnated micropolishing points, then the nanotechnology liquid polish system
Number of subjects: 40
Study 20533638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 18230972 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 88
Study 16699814 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day Pycnogenol
Number of subjects: 61
Study 16699814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 14596629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Number of subjects: 2
Study 14596629 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide
Number of subjects: 2
Study 10957700 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen per os and topical placebo
Number of subjects: 24
Study 10957700 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of a 5% commercial ibuprofen gel topically applied and oral placebo capsules
Number of subjects: 24
Study 10957700 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral ibuprofen
Number of subjects: 24
Study 10957700 — intervention group
Group type: COMPARATOR
Intervention: Commercial ibuprofen gel
Number of subjects: 24
Study 8771007 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 4 IU/m2/day subcutaneously for 6 months
Number of subjects: 11
Study 8771007 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 11
Study 8771007 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 11
Study 1295221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoelectrotherapy
Number of subjects: 110
Study 1295221 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 110
Study 1295221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo- or cryoelectrotherapy
Number of subjects: 110
Study 6730991 — intervention group
Group type: EXPERIMENTAL
Intervention: Community treatment provided by the Community Treatment Team, including comprehensive community treatment and a 24-h crisis service.
Number of subjects: 65
Study 6730991 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care and after-care (Control group).
Number of subjects: 65
Study 6730991 — intervention group
Group type: EXPERIMENTAL
Intervention: Community treatment (Experimental group).
Number of subjects: 65
Study 30703216 — intervention group
Group type: EXPERIMENTAL
Intervention: Story sharing intervention (sharing stories in groups) over 3 weeks with 2 to 3 participants sharing five stories.
Number of subjects: 93
Study 30703216 — intervention group
Group type: COMPARATOR
Intervention: Baseline sociodemographic characteristics.
Number of subjects: 93
Study 30044162 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily combined with metformin 500 mg three times daily (Group A)
Number of subjects: 200
Study 30044162 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin and metformin individually (Group B)
Number of subjects: 200
Study 30044162 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin and metformin individually (Group C)
Number of subjects: 200
Study 26583379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine lidocaine
Number of subjects: 206
Study 26583379 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin
Number of subjects: 206
Study 26583379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 24730357 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week multicomponent intervention
Number of subjects: 494
Study 24730357 — intervention group
Group type: COMPARATOR
Intervention: brief workshop control group
Number of subjects: 494
Study 22383118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a (Peg‐IFN‐α2a) ± ribavirin for 24 weeks
Number of subjects: 114
Study 22383118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a (Peg‐IFN‐α2a) ± ribavirin for 48 weeks
Number of subjects: 114
Study 22383118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a (Peg‐IFN‐α2a) ± ribavirin for 72 weeks
Number of subjects: 114
Study 20697836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT) to maintain blood glucose levels from 80 to 110 mg/dl
Number of subjects: 81
Study 20697836 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment to maintain blood glucose levels less than 151 mg/dl
Number of subjects: 81
Study 20697836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 81
Study 20697836 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 81
Study 17490958 — intervention group
Group type: EXPERIMENTAL
Intervention: High-AGE meal (HAGE)
Number of subjects: 20
Study 17490958 — intervention group
Group type: COMPARATOR
Intervention: Low-AGE meal (LAGE)
Number of subjects: 20
Study 16197282 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-channel, slow-acting wide dynamic range amplitude compression (WDRC)
Number of subjects: 2
Study 16197282 — intervention group
Group type: COMPARATOR
Intervention: Linear amplification
Number of subjects: 2
Study 11892710 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 200 mg
Number of subjects: 83
Study 11892710 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 100 mg
Number of subjects: 83
Study 11892710 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 50 mg
Number of subjects: 83
Study 11892710 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 25 mg
Number of subjects: 83
Study 11892710 — intervention group
Group type: EXPERIMENTAL
Intervention: All Neridronate doses
Number of subjects: 83
Study 11892710 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate
Number of subjects: 83
Study 11113693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap 1846SX (DIN)
Number of subjects: 105
Study 11113693 — intervention group
Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer (SMS)
Number of subjects: 105
Study 8967094 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at a dosage of 60 micrograms over 2 hours
Number of subjects: 13
Study 8967094 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 13
Study 1454387 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 0
Study 1454387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 0
Study 4048832 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin infusion (3 CU/kg/h)
Number of subjects: 19
Study 4048832 — intervention group
Group type: COMPARATOR
Intervention: Secretin bolus (2 CU/kg)
Number of subjects: 19
Study 31307814 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRF-guided neck dissection
Number of subjects: 31
Study 31307814 — intervention group
Group type: COMPARATOR
Intervention: Conventional neck dissection
Number of subjects: 31
Study 29726731 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1 mA, 20 min × 5 days)
Number of subjects: 29
Study 29726731 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study 29726731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondominant-hand 30-Hz VDT
Number of subjects: 29
Study 29726731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency VDT
Number of subjects: 29
Study 29726731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondominant-hand VDT
Number of subjects: 29
Study 27442225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages with long-term consequences
Number of subjects: 0
Study 27442225 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages with short-term consequences
Number of subjects: 0
Study 24020449 — intervention group
Group type: EXPERIMENTAL
Intervention: milTBI (blast-related military TBI)
Number of subjects: 87
Study 24020449 — intervention group
Group type: EXPERIMENTAL
Intervention: civTBI (non-blast civilian TBI)
Number of subjects: 87
Study 24020449 — intervention group
Group type: COMPARATOR
Intervention: milCON (military controls)
Number of subjects: 87
Study 24020449 — intervention group
Group type: COMPARATOR
Intervention: civCON (civilian controls)
Number of subjects: 87
Study 22489522 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-segment pedicle screw fixation through the gap of paravertebral muscles
Number of subjects: 65
Study 22489522 — intervention group
Group type: COMPARATOR
Intervention: Double-segment pedicle screw fixation through the stripping of paravertebral muscles
Number of subjects: 65
Study 20692797 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET) with at least two training sessions per week, each lasting over 30 minutes during the first 3 months.
Number of subjects: 169
Study 20692797 — intervention group
Group type: EXPERIMENTAL
Intervention: SET with at least 590 minutes of training in the first 3 months.
Number of subjects: 169
Study 20692797 — intervention group
Group type: COMPARATOR
Intervention: SET involving only walking vs. a combination of exercises.
Number of subjects: 169
Study 20692797 — intervention group
Group type: COMPARATOR
Intervention: Individual vs. group training.
Number of subjects: 169
Study 18948373 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance plus eye movement exercises (n=10)
Number of subjects: 19
Study 18948373 — intervention group
Group type: COMPARATOR
Intervention: Balance exercises only (n=9)
Number of subjects: 19
Study 15906080 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max(m)(-0.32)
Number of subjects: 79
Study 15906080 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in VO2max from 2.36 l min(-1) to 3.44 l min(-1)
Number of subjects: 79
Study 15906080 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in VO2max from 4.77 l min(-1) to 6.36 l min(-1)
Number of subjects: 79
Study 15906080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling with a side wind
Number of subjects: 79
Study 12589361 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus strains (Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 122460) given for 6 weeks
Number of subjects: 0
Study 12589361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10367990 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients (both genders)
Number of subjects: 140
Study 10367990 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed women
Number of subjects: 140
Study 10367990 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed volunteers
Number of subjects: 140
Study 7589684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cell blocker (tranilast) 300 mg/d for 3 months
Number of subjects: 50
Study 7589684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2404878 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐monthly screening by chest X‐ray and sputum cytology
Number of subjects: 6364
Study 2404878 — intervention group
Group type: COMPARATOR
Intervention: No asymptomatic investigation (Control)
Number of subjects: 6364
Study 7364521 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional trance induction procedure emphasizing relaxation and passivity
Number of subjects: 82
Study 7364521 — intervention group
Group type: COMPARATOR
Intervention: No induction (control) treatment
Number of subjects: 82
Study 30136637 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-collar group (n = 11)
Number of subjects: 23
Study 30136637 — intervention group
Group type: COMPARATOR
Intervention: Collar group (n = 12)
Number of subjects: 23
Study 30136637 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-collar group (n = 10)
Number of subjects: 23
Study 28094482 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound guidance for spinal anesthesia
Number of subjects: 38
Study 28094482 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique for spinal anesthesia
Number of subjects: 38
Study 25350973 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir with optimized background therapy (OBT)
Number of subjects: 0
Study 23497575 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex multifaceted intervention incorporating academic detailing, medicines review with web-based pharmaceutical treatment algorithms, and tailored patient information leaflets.
Number of subjects: 220
Study 23497575 — intervention group
Group type: COMPARATOR
Intervention: Usual care with simple patient-level feedback on potentially inappropriate prescribing.
Number of subjects: 220
Study 22333096 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuangong Cu 365 (YCu365)
Number of subjects: 24000
Study 22333096 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 380A (TCu380A)
Number of subjects: 24000
Study 22333096 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload Cu 375 (MLCu375)
Number of subjects: 24000
Study 22333096 — intervention group
Group type: COMPARATOR
Intervention: YCu365, TCu380A, MLCu375
Number of subjects: 24000
Study 20449934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rapamycin plus bare metal stents (OR + BMS)
Number of subjects: 200
Study 20449934 — intervention group
Group type: COMPARATOR
Intervention: Drug eluting stents (DES)
Number of subjects: 200
Study 17276032 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer rejection condition
Number of subjects: 115
Study 17276032 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer success condition
Number of subjects: 115
Study 17276032 — intervention group
Group type: COMPARATOR
Intervention: Neutral peer feedback condition
Number of subjects: 115
Study 14665566 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with CPB
Number of subjects: 40
Study 14665566 — intervention group
Group type: COMPARATOR
Intervention: Propofol without CPB (off-pump)
Number of subjects: 40
Study 11157558 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lesions in occipitoparietal and parietotemporal areas
Number of subjects: 50
Study 11157558 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lesions involving anterior temporal or parietal lobes
Number of subjects: 50
Study 11157558 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lesions involving the human homologue of MT
Number of subjects: 50
Study 11157558 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study 11157558 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MT/V5 lesions
Number of subjects: 50
Study 11157558 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dynamic visual noise
Number of subjects: 50
Study 9431344 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention for acute appendicitis
Number of subjects: 0
Study 9431344 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 0
Study 9431344 — intervention group
Group type: COMPARATOR
Intervention: Early operation compared with intravenous antibiotics with or without drainage
Number of subjects: 0